Apellis Pharmaceuticals Overview
Valuation check: APLS's P/E ratio is 38.71, above the Healthcare sector average of 27.42.
Get informed when a big investor buys or sells
+ Follow38.71
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Apellis Pharmaceuticals (APLS) currently reports a P/E ratio of 38.71. That is above the Healthcare sector average of 27.42. Use the charts on this page to explore Apellis Pharmaceuticals's P/E ratio history and peer comparisons.
Apellis Pharmaceuticals's P/E ratio of 38.71 is higher than the Healthcare sector average of 27.42. That is roughly 41.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Apellis Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 38.71, APLS can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 38.71, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.42. From there, open related valuation or income-statement pages for Apellis Pharmaceuticals, and consider following APLS for alerts when major investors trade the stock.
Apellis Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows 38.71 versus a sector average near 27.42. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing APLS with unrelated industries.
